Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plasma mitomycin C concentrations determined by HPLC coupled to solid-phase extraction

R Paroni1, C Arcelloni, E De Vecchi

  • 1Laboratory of Chromatography and Separative Techniques, I.R.C.C.S. H San Raffaele, Milano, Italy.

Clinical Chemistry
|April 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Re-evaluating antibody-drug conjugate linker stability: assessment, interpretation, and clinical translation.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

TAMs and PD-1 networking in esophageal cancer: literature review.

ESMO gastrointestinal oncology·2026
Same author

Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study.

ESMO real world data and digital oncology·2026
Same author

Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer.

ESMO gastrointestinal oncology·2026
Same author

Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece.

Expert review of pharmacoeconomics & outcomes research·2025
Same author

Real-World Treatment Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer in Greece: The PROSPECT Study.

Clinical genitourinary cancer·2024
Same journal

From Pooled Cohorts to PREVENT: A Perspective for Clinical Laboratorians.

Clinical chemistry·2026
Same journal

Interlaboratory Comparison of a Glucagon and Oxyntomodulin Immuno-LC-MS/MS Assay: Implications for Diabetes Research.

Clinical chemistry·2026
Same journal

Comparison of Information-Dependent Acquisition and Sequential Window Acquisition of All Theoretical Mass Spectra for Untargeted Drug Testing on a Linear Ion Trap-Pulsing Quadrupole-Time of Flight Mass Spectrometer.

Clinical chemistry·2026
Same journal

Patterns of One-Year Change in HbA1c and Continuous Glucose Monitoring (CGM) Metrics in Older Adults with Type 2 Diabetes.

Clinical chemistry·2026
Same journal

TSH Pediatric Reference Intervals: Lack of CALIPER Applicability to US-Based Populations.

Clinical chemistry·2026
Same journal

Rapid Detection of Hemoglobinopathy Variants Using One-Step Library Preparation and Nanopore Sequencing.

Clinical chemistry·2026
See all related articles

This study presents a simple and efficient method for quantifying plasma mitomycin C (MMC) concentrations during intravesical chemotherapy with hyperthermia (HT). The assay is suitable for routine clinical monitoring of MMC pharmacokinetics in bladder cancer patients.

Area of Science:

  • Pharmacology
  • Analytical Chemistry
  • Oncology

Background:

  • Intravesical chemotherapy with mitomycin C (MMC) combined with hyperthermia (HT) is a treatment for superficial bladder cancer.
  • Accurate quantification of plasma MMC concentrations is crucial for pharmacokinetic monitoring.
  • Existing methods for MMC quantification may be complex or require specialized equipment.

Purpose of the Study:

  • To develop and validate a straightforward and efficient method for quantifying plasma mitomycin C (MMC) concentrations.
  • To facilitate pharmacokinetic monitoring of MMC during intravesical chemotherapy with local bladder hyperthermia (HT).
  • To enable the use of non-specialized instrumentation and staff for MMC quantification.

Main Methods:

  • Plasma samples were purified using solid-phase extraction under vacuum.

Related Experiment Videos

  • Chromatographic analysis was performed using High-Performance Liquid Chromatography (HPLC) with a reversed-phase C18 column.
  • Quantification utilized UV detection at 365 nm with porfiromycin as the internal standard.

    • Main Results:

    • The developed assay demonstrated good within-day precision (CV 6.0%) and linearity (0.5-50 µg/L).
    • The method exhibited specificity and a low limit of detection (≤ 0.5 µg/L).
    • The assay proved suitable for plasma pharmacokinetic monitoring in patients treated with MMC + HT.

    Conclusions:

    • A simple, efficient, and validated method for plasma MMC quantification has been established.
    • This assay facilitates pharmacokinetic monitoring in patients undergoing intravesical MMC + HT for bladder cancer.
    • The method's ease of use and requirement for non-specialized equipment support its clinical application.